Table 3 Participants characteristics according to transient elastography results
Altered TE | Normal TE | p value | |
|---|---|---|---|
Demographical and clinical characteristics | |||
N (%) | 22 (23.2) | 73 (76.8) | |
Age, years | 40 ± 11 | 39 ± 14 | 0.625 |
Female gender, n (%) | 11 (50.0) | 44 (60.3) | 0.392 |
Non-Caucasian, n (%) | 9 (40.9) | 39 (53.4) | 0.303 |
Years of school attendance | 12 ± 4 | 12 ± 3 | 0.833 |
Diabetes duration, years | 22 ± 10 | 20 ± 9 | 0.448 |
BMI, kg/m2 | 28.9 ± 3.7 | 24.3 ± 3.6 | < 0.001 |
WC, cm | 94.9 ± 11.3 | 83.2 ± 10.4 | < 0.001 |
HC, cm | 104.5 ± 7.4 | 97.8 ± 7.0 | < 0.001 |
WHR | 0.91 ± 0.08 | 0.85 ± 0.07 | 0.003 |
SBP, mmHg | 135 ± 16 | 125 ± 16 | 0.011 |
DBP, mmHg | 81 ± 11 | 76 ± 10 | 0.027 |
Insulin dose, U/kg | 0.75 ± 0.26 | 0.77 ± 0.33 | 0.768 |
Hypertension, n (%) | 14 (63.6) | 29 (39.7) | 0.048 |
Anti-hypertensive use, n (%) | 13 (59.1) | 26 (35.6) | 0.050 |
Metformin use, n (%) | 5 (22.7) | 6 (8.2) | 0.120 |
Statin use, n (%) | 14 (63.6) | 30 (41.1) | 0.063 |
Acetylsalicylic acid use, n (%) | 6 (27.3) | 12 (16.4) | 0.351 |
Currently smoking, n (%) | 1 (4.5) | 5 (5.3) | 1.000 |
Metabolic syndrome, n (%) | 15 (68.2) | 27 (37.0) | 0.010 |
FLI | 60 [58] | 13 [21] | < 0.001 |
Laboratory measurements | |||
HbA1c (%) mmol/mol | 8.9 [2.8] 74 [29] | 8.5 [2.3] 70 [24] | 0.717 |
FPG,mg/dl | 130 [200] | 116 [131] | 0.517 |
Total cholesterol, mg/dl | 170.0 [77.3] | 161.0 [65.0] | 0.880 |
HDL-c, mg/dl | 50.8 [24.5] | 47.6 [32.8] | 0.880 |
LDL-c, mg/dl | 99.9 [46.1] | 91.4 [40.2] | 0.383 |
Triglycerides, mg/dl | 89.0 [99.0] | 75.0 [62.5] | 0.040 |
eGFR, ml/min/1.73 m2 | 99 [30] | 100 [29] | 0.771 |
Albumin, mg/dl | 4.0 ± 0.7 | 4.0 ± 0.6 | 0.992 |
ALT, U/l | 10.0 [8.5] | 8.0 [7.0] | 0.260 |
AST, U/l | 14.5 [8.3] | 12.0 [7.5] | 0.082 |
GGT, mg/dl | 20.5 [41.3] | 19.0 [16.5] | 0.596 |
CPK, mg/dl | 119.0 [172.0] | 80.0 [86.0] | 0.667 |
CRP, mg/dl | 0.3 [0.9] | 0.2 [0.4] | 0.771 |
Uric acid, mg/dl | 3.8 [1.8] | 3.5 [1.7] | 0.383 |